Crinetics Pharmaceuticals Inc Earnings

Crinetics Pharmaceuticals Inc’s revenue fell -100% since last year same period to $0Mn in the Q3 2024. On a quarterly growth basis, Crinetics Pharmaceuticals Inc has generated -100% fall in its revenue since last 3-months.

Crinetics Pharmaceuticals Inc’s net profit fell -33.71% since last year same period to $-76.83Mn in the Q3 2024. On a quarterly growth basis, Crinetics Pharmaceuticals Inc has generated -3.74% fall in its net profits since last 3-months.

Crinetics Pharmaceuticals Inc’s net profit margin fell -Inf% since last year same period to -Inf% in the Q3 2024. On a quarterly growth basis, Crinetics Pharmaceuticals Inc has generated -Inf% fall in its net profit margins since last 3-months.

Crinetics Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.91 - a -5.81% fall from last quarter’s estimates.

Crinetics Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.91.

Crinetics Pharmaceuticals Inc’s earning per share (EPS) jumped 4.95% since last year same period to -0.96 in the Q3 2024. This indicates that the Crinetics Pharmaceuticals Inc has generated 4.95% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Crinetics Pharmaceuticals Inc’s return on assets (ROA) stands at -0.24.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Crinetics Pharmaceuticals Inc’s return on equity (ROE) stands at -0.4.